Comprehensive Stock Comparison
Compare Novavax, Inc. (NVAX) vs Scinai Immunotherapeutics Ltd. (SCNI) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SCNI | 303.9% revenue growth vs NVAX's 64.7% |
| Value | SCNI | Lower P/E (0.1x vs 3.9x) |
| Quality / Margins | SCNI | 401.8% net margin vs NVAX's 39.2% |
| Stability / Safety | SCNI | Beta 0.60 vs NVAX's 1.25 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | NVAX | +21.7% vs SCNI's -74.9% |
| Efficiency (ROA) | SCNI | 38.9% ROA vs NVAX's 37.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Novavax is a biotechnology company that develops and commercializes protein-based vaccines for serious infectious diseases. It generates revenue primarily from its COVID-19 vaccine sales and government contracts, with future potential from its pipeline including seasonal flu and RSV vaccines. The company's key advantage is its proprietary recombinant nanoparticle vaccine technology platform, which enables rapid development of vaccines with demonstrated efficacy.
Scinai Immunotherapeutics is a development-stage biopharmaceutical company focused on creating nanosized antibody therapies for infectious and autoimmune diseases. It generates revenue primarily through research collaborations and licensing agreements — notably with the Max Planck Society — while advancing its COVID-19 NanoAb and other pipeline candidates. The company's key advantage lies in its proprietary NanoAb platform technology, which aims to create smaller, potentially more effective antibody therapies compared to conventional antibodies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
NVAX leads in 2 of 6 categories (Financial Metrics, Total Returns). SCNI leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
NVAX is the larger business by revenue, generating $1.1B annually — 979.5x SCNI's $1M. Profitability is closely matched — net margins range from 4.0% (SCNI) to 39.2% (NVAX). On growth, NVAX holds the edge at +66.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| RevenueTrailing 12 months | $1.1B | $1M |
| EBITDAEarnings before interest/tax | $453M | -$7M |
| Net IncomeAfter-tax profit | $440M | $5M |
| Free Cash FlowCash after capex | -$251M | -$6M |
| Gross MarginGross profit ÷ Revenue | +93.5% | -147.0% |
| Operating MarginEBIT ÷ Revenue | +40.3% | -7.4% |
| Net MarginNet income ÷ Revenue | +39.2% | +4.0% |
| FCF MarginFCF ÷ Revenue | -22.3% | -5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +66.6% | +36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +158.8% | +66.7% |
Valuation Metrics
At 0.1x trailing earnings, SCNI trades at a 96% valuation discount to NVAX's 3.9x P/E.
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Market CapShares × price | $1.7B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | 3.93x | 0.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 3.71x | — |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 4607.73x |
| Price / BookPrice ÷ Book value/share | — | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| ROE (TTM)Return on equity | — | +58.7% |
| ROA (TTM)Return on assets | +37.4% | +38.9% |
| ROICReturn on invested capital | — | -61.1% |
| ROCEReturn on capital employed | +80.7% | -63.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | — | 0.21x |
| Net DebtTotal debt minus cash | $8M | $122,000 |
| Cash & Equiv.Liquid assets | $241M | $2M |
| Total DebtShort + long-term debt | $249M | $2M |
| Interest CoverageEBIT ÷ Interest expense | — | 3.35x |
Total Returns (with DRIP)
A $10,000 investment in NVAX five years ago would be worth $422 today (with dividends reinvested), compared to $20 for SCNI. Over the past 12 months, NVAX leads with a +21.7% total return vs SCNI's -74.9%. The 3-year compound annual growth rate (CAGR) favors NVAX at 3.1% vs SCNI's -66.5% — a key indicator of consistent wealth creation.
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| YTD ReturnYear-to-date | +42.2% | +21.7% |
| 1-Year ReturnPast 12 months | +21.7% | -74.9% |
| 3-Year ReturnCumulative with dividends | +9.5% | -96.2% |
| 5-Year ReturnCumulative with dividends | -95.8% | -99.8% |
| 10-Year ReturnCumulative with dividends | -88.4% | -99.8% |
| CAGR (3Y)Annualised 3-year return | +3.1% | -66.5% |
Risk & Volatility
SCNI is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than NVAX's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVAX currently trades 84.7% from its 52-week high vs SCNI's 14.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.60x |
| 52-Week HighHighest price in past year | $11.97 | $6.18 |
| 52-Week LowLowest price in past year | $5.01 | $0.61 |
| % of 52W HighCurrent price vs 52-week peak | +84.7% | +14.4% |
| RSI (14)Momentum oscillator 0–100 | 74.8 | 52.3 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 42K |
Analyst Outlook
| Metric | NVAXNovavax, Inc. | SCNIScinai Immunother… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $14.50 | — |
| # AnalystsCovering analysts | 23 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Novavax, Inc. (NVAX) | 100 | 72.3 | -27.7% |
| Scinai Immunotherap… (SCNI) | 100 | 0.12 | -99.9% |
Novavax, Inc. (NVAX) returned -96% over 5 years vs Scinai Immunotherap… (SCNI)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Novavax, Inc. (NVAX) | $15M | $1.1B | +7217.7% |
| Scinai Immunotherap… (SCNI) | $0.00 | $658000.00 | — |
Novavax, Inc.'s revenue grew from $15M (2016) to $1.1B (2025) — a 61.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Novavax, Inc. (NVAX) | -18.2% | 39.2% | +314.9% |
| Scinai Immunotherap… (SCNI) | 7.3% | 7.3% | +0.0% |
Novavax, Inc.'s net margin went from -18% (2016) to 39% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Novavax, Inc. (NVAX) | -20.68 | 2.58 | +112.5% |
| Scinai Immunotherap… (SCNI) | -282,320 | 6 | +100.0% |
Novavax, Inc.'s EPS grew from $-20.68 (2016) to $2.58 (2025).
Chart 5Free Cash Flow — 5 Years
Novavax, Inc. generated $-250M FCF in 2025 (-194% vs 2021). Scinai Immunotherapeutics Ltd. generated $-6M FCF in 2024 (+16% vs 2021).
NVAX vs SCNI: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NVAX or SCNI a better buy right now?
Scinai Immunotherapeutics Ltd. (SCNI) offers the better valuation at 0.1x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NVAX or SCNI?
On trailing P/E, Scinai Immunotherapeutics Ltd. (SCNI) is the cheapest at 0.1x versus Novavax, Inc. at 3.9x.
03Which is the better long-term investment — NVAX or SCNI?
Over the past 5 years, Novavax, Inc. (NVAX) delivered a total return of -95.8%, compared to -99.8% for Scinai Immunotherapeutics Ltd. (SCNI). A $10,000 investment in NVAX five years ago would be worth approximately $422 today (assuming dividends reinvested). Over 10 years, the gap is even starker: NVAX returned -88.4% versus SCNI's -99.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NVAX or SCNI?
By beta (market sensitivity over 5 years), Scinai Immunotherapeutics Ltd. (SCNI) is the lower-risk stock at 0.60β versus Novavax, Inc.'s 1.25β — meaning NVAX is approximately 107% more volatile than SCNI relative to the S&P 500.
05Which has better profit margins — NVAX or SCNI?
Scinai Immunotherapeutics Ltd. (SCNI) is the more profitable company, earning 728.9% net margin versus 39.2% for Novavax, Inc. — meaning it keeps 728.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 40.3% versus -1312.8% for SCNI. At the gross margin level — before operating expenses — NVAX leads at 93.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NVAX or SCNI?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NVAX or SCNI better for a retirement portfolio?
For long-horizon retirement investors, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.60)). Both have compounded well over 10 years (SCNI: -99.8%, NVAX: -88.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NVAX and SCNI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.